Background & Objective: The inactivation and low expression of tumor suppressor gene p16 has been found to play an important role in the tumorigenesis of a wide variety of human tumors, but its association with human pituitary adenomas was not clear. This study was conducted to investigate the relationship between p16 gene expression and clinicopathologic features including invasiveness and recurrence in pituitary adenoma patients.
Methods: The p16 mRNA and p16 protein expression levels were examined using reverse transcription polymerase chain reaction (RT-PCR) and Western Blot analysis respectively in 70 pituitary adenomas and 10 normal brain tissues.
Results: Fifty-two of 70 (74.3%) tumor samples presented loss or low p16 mRNA and p16 protein. The invasive and recurrent adenomas had higher loss expression rates than noninvasive and nonrecurrent group respectively; however, there was no significant difference (P >0.05). Moreover, the mean diameter of adenomas without p16 expression was obviously larger than that of p16-positive tumors (22.1+/-7.2 mm versus 8.1+/-4.5 mm, P< 0.01). There was no association between p16 expression and other clinicopathologic features of pituitary adenomas.
Conclusion: These findings suggested that p16 down-regulation may play an important role in the initial tumorigenesis, growth, and biological behavior of pituitary adenomas.
Download full-text PDF |
Source |
---|
Pituitary
January 2025
Department of Neurological Surgery, University of Miami Miller School of Medicine, 1095 NW 14th Terrace, 2nd Floor, Miami, Fl, 33136, USA.
Purpose: Prolonged length of stay (PLOS) can lead to resource misallocation and higher complication risks. However, there is no consensus on defining PLOS for endoscopic transsphenoidal pituitary surgery (ETPS). Therefore, we investigated the impact of varying PLOS definitions on factors associated with PLOS in patients undergoing ETPS.
View Article and Find Full Text PDFPituitary
January 2025
Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA.
Purpose: Pituitary adenomas, despite their histologically benign nature, can severely impact patients' quality of life due to hormone hypersecretion. Invasion of the medial wall of the cavernous sinus (MWCS) by these tumors complicates surgical outcomes, lowering biochemical remission rates and increasing recurrence. This study aims to share our institutional experience with the selective resection of the MWCS in endoscopic pituitary surgery.
View Article and Find Full Text PDFRev Endocr Metab Disord
January 2025
Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
An 'adenoma' is a benign neoplasm composed of epithelial tissue, and has been standard nomenclature for primary pituitary neoplasms. In 2022, the fifth edition of the WHO Classification of Endocrine Tumours and of Central Nervous System Tumours, renamed pituitary adenomas as neuroendocrine tumours (NETs), assigning an oncology label to pituitary invariably benign neoplasms. Multidisciplinary workshops convened by the Pituitary Society have questioned the process, validity, and merit of this arbitrary change, while addressing the adverse clinical implications of the proposed new nomenclature.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Department of Neurosurgery, Odense University Hospital, DK-5000 Odense, Denmark.
Pituitary adenomas are a diverse group of neoplasms with variable clinical behavior. Despite advances in genetic analysis, understanding the role of epigenetic modifications, particularly DNA methylation, remains an area under investigation. This scoping review aimed to update and synthesize the current body of literature on DNA methylation in pituitary adenomas, focusing on methodological advancements and clinical correlations.
View Article and Find Full Text PDFWorld Neurosurg
January 2025
Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, China. Electronic address:
Objective: To summarize the clinical characteristics, pituitary function assessment, postoperative pathological features, and postoperative recurrence of surgically treated pituitary adenomas (PAs).
Methods: We retrospectively reviewed the data of 338 patients (169 women; average age: 50.01 ± 12.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!